DelveInsight Business Research LLP

DelveInsight’s “Chondrosarcoma Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Chondrosarcoma Overview

Chondrosarcomas are large tumors, usually greater than 4 cm in size [5]. They have a translucent lobular, blue-grey, or white cut surface corresponding to the presence of hyaline cartilage. There may be areas containing myxoid or mucoid material and cystic changes.

A type of cancer that forms in bone cartilage. It usually starts in the pelvis (between the hip bones), the shoulder, the ribs, or at the ends of the long bones of the arms and legs. A rare type of chondrosarcoma called extraskeletal chondrosarcoma does not form in bone cartilage. Instead, it forms in the soft tissues of the upper part of the arms and legs. Chondrosarcoma can occur at any age but is more common in people over 40. It is a type of bone cancer.

Chondrosarcoma Epidemiology Insights

• Chondrosarcoma is the second most common primary bone sarcoma. The incidence of chondrosarcoma is approximately 1 per 100,000 individuals worldwide.

• Chondrosarcoma is most frequently diagnosed in patients in their 4th and 5th decades of life. The average age at presentation is 51 years.

• The male-to-female ratio is almost 1:1 except for clear cell chondrosarcoma, it is 2.4:1.

Click here to learn more about the Chondrosarcoma Market Landscape

The Report Covers the Chondrosarcoma Epidemiology Segmented by:

• Chondrosarcoma incidence cases 

• Chondrosarcoma cases based on gender

• Chondrosarcoma cases based on age

• Chondrosarcoma cases based on race

Chondrosarcoma Market Outlook 

For both appendicular and axial chondrosarcomas, surgical treatment remains the mainstay of treatment due to its continued superiority for the long-term survival of patients, although advancements in survival over the last decade have been insignificant. Rarer chondrosarcoma subtypes are more responsive to chemotherapy and radiation therapy. Chemotherapy is generally ineffective in conventional chondrosarcoma, and there is no standard systemic therapy for advanced conventional chondrosarcoma. Moreover, the current chemotherapy recommendations include cisplatin and doxorubicin, which are extrapolated from recommended osteosarcoma treatment regimens. The current market has been based on the prevailing treatment pattern across the 7MM, which presents minor variations in the overall prescription pattern. Chemotherapy, radiation + chemotherapy, and others such as pazopanib, regorafenib, and dasatinib are the current treatment options in the forecast model.

Key Companies Working in the Chondrosarcoma Market

• Inhibrx

• GlaxoSmithKline

• Infinity Pharmaceuticals 

• Salarius Pharmaceuticals 

• Tracon Pharmaceuticals 

And many others 

Chondrosarcoma Therapies Covered and Analyzed in the Report:

•  Pazopanib

•  INBRX-109

•  IPI-926

• Trabectedin

•  Loperamide

And many other things 

Learn more about the Key Companies and Emerging Therapies in the Chondrosarcoma    Market

Table of Contents 

1. Key Insights 

2. Chondrosarcoma Introduction 

3. Executive Summary of Chondrosarcoma      

4. Disease Background and Overview

5. Epidemiology and patient population

6. Chondrosarcoma Emerging Therapies

7. Chondrosarcoma Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Chondrosarcoma Market Outlook

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting